Crossmark

A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab

Published Online: 2024-11-20

Published Print: 2024-12

Authors

Abdelhalim, Asaad https://orcid.org/0000-0001-7392-5256
Yilmaz, Orhan https://orcid.org/0000-0002-7764-3229
Elshaikh Berair, Mohamed https://orcid.org/0009-0002-7350-3840
Torres, Tiago https://orcid.org/0000-0003-0404-0870
License Information

Text and Data Mining valid from 2024-11-20

Version of Record valid from 2024-11-20
More Information

Article History

Received: 10 October 2024

Accepted: 4 November 2024

First Online: 20 November 2024

Declarations

:

: Orhan Yilmaz has nothing to disclose. Asaad Abdelhalim has nothing to disclose. Mohamed Elshaikh Berair has nothing to disclose. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB. Tiago Torres is an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current